Rhythm is a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare MC4R pathway diseases. The company is leveraging the Rhythm Engine -- comprised of its TEMPO Registry, GO-ID genotyping study and Uncovering Rare Obesity program -- to improve the understanding, diagnosis and potentially the treatment of these disorders. For healthcare professionals, visit www.RareObesity.com for more information. For patients and caregivers, visit www.LEADforRareObesity.com for more information.